Skip to main content
NCBI home page
Heart logoLink to Heart
. 2000 Nov;84(5):541–547. doi: 10.1136/heart.84.5.541

Haemochromatosis gene mutations in idiopathic dilated cardiomyopathy

N Mahon 1, A Coonar 1, S Jeffery 1, F Coccolo 1, J Akiyu 1, B Zal 1, R Houlston 1, G Levin 1, C Baboonian 1, W McKenna 1, G BAXTER 1
PMCID: PMC1729493  PMID: 11040018

Abstract

BACKGROUND—Two common mutations of the haemochromatosis associated gene (HFE) (cys282tyr (C282Y) and his63asp (H63D)) have been implicated in haemochromatosis and as modulators in cardiovascular disease.
OBJECTIVE—To investigate the role of these mutations in the pathogenesis of idiopathic dilated cardiomyopathy.
DESIGN AND SETTING—Case-control and prospective cohort study of patients attending a cardiomyopathy unit in a tertiary referral cardiac centre.
METHODS—207 unrelated white patients with dilated cardiomyopathy, followed up for 259 patient years, and 200 controls were tested for HFE C282Y and H63D mutations by polymerase chain reaction and restriction digestion.
RESULTS—31/207 patients (15%) v 24/200 controls (12%) carried C282Y (adjusted odds ratio (OR) 1.2 (95% confidence interval 0.7 to 2.2)), 74/207 (36%) v 53/200 (27%) carried H63D (OR 1.6 (1.1 to 2.5)), and 10/207 (4.8%) v 4/200 (2%) were compound heterozygotes (OR 2.6 (0.8 to 8.5)). Four patients and six controls were H63D homozygous and one was C282Y homozygous. There was a progressive increase in mean serum iron ([Fe]) and transferrin saturations from patients with no mutation ([Fe] = 16.3 µmol/l, transferrin saturation = 23.7%) through H63D heterozygotes (17.5 µmol/l, 25.8%), C282Y heterozygotes (17.1 µmol/l, 26.6%), H63D homozygotes (20.0 µmol/l, 33.5%), compound heterozygotes (26.8 µmol/l, 41.7%), and C282Y homozygotes (34 µmol/l, 71%). At follow up (median 90 months) the rate of death or cardiac transplantation was 52/207 (25%). C282Y heterozygotes had less ventricular dilatation (mean (SD): 59.9 (1.7) mm v 64.9 (0.9) mm, p < 0.05), better fractional shortening (24 (1.7)% v 18.8 (1.4)%, p < 0.01), and a trend towards improved survival without transplantation. [Fe] and transferrin saturation did not correlate with disease severity and were not associated with reduced survival.
CONCLUSIONS—The frequency of the H63D mutation is significantly increased in patients with idiopathic dilated cardiomyopathy. As H63D has a relatively minor effect on iron status, the mechanism of this association may be unrelated to iron metabolism.


Keywords: dilated cardiomyopathy; genetics; haemochromatosis

Full Text

The Full Text of this article is available as a PDF (147.5 KB).

Figure 1  .

Figure 1  

Open in a new tab

Death or transplant-free survival of patients carrying the C282Y variant allele.

Figure 2  .

Figure 2  

Open in a new tab

Death or transplant-free survival of patients carrying the H63D variant allele.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams P. C., Chakrabarti S. Genotypic/phenotypic correlations in genetic hemochromatosis: evolution of diagnostic criteria. Gastroenterology. 1998 Feb;114(2):319–323. doi: 10.1016/s0016-5085(98)70483-4. [DOI] [PubMed] [Google Scholar]
  2. Aguilar Martinez P., Biron C., Blanc F., Masmejean C., Jeanjean P., Michel H., Schved J. F. Compound heterozygotes for hemochromatosis gene mutations: may they help to understand the pathophysiology of the disease? Blood Cells Mol Dis. 1997 Aug;23(2):269–276. doi: 10.1006/bcmd.1997.0143. [DOI] [PubMed] [Google Scholar]
  3. Arosa F. A., da Silva A. J., Godinho I. M., ter Steege J. C., Porto G., Rudd C. E., de Sousa M. Decreased CD8-p56lck activity in peripheral blood T-lymphocytes from patients with hereditary haemochromatosis. Scand J Immunol. 1994 May;39(5):426–432. doi: 10.1111/j.1365-3083.1994.tb03396.x. [DOI] [PubMed] [Google Scholar]
  4. Beutler E. Genetic irony beyond haemochromatosis: clinical effects of HLA-H mutations. Lancet. 1997 Feb 1;349(9048):296–297. doi: 10.1016/S0140-6736(97)22005-2. [DOI] [PubMed] [Google Scholar]
  5. Bonkovsky H. L., Ponka P., Bacon B. R., Drysdale J., Grace N. D., Tavill A. S. An update on iron metabolism: summary of the Fifth International Conference on Disorders of Iron Metabolism. Hepatology. 1996 Sep;24(3):718–729. doi: 10.1002/hep.510240341. [DOI] [PubMed] [Google Scholar]
  6. Bowles K. R., Gajarski R., Porter P., Goytia V., Bachinski L., Roberts R., Pignatelli R., Towbin J. A. Gene mapping of familial autosomal dominant dilated cardiomyopathy to chromosome 10q21-23. J Clin Invest. 1996 Sep 15;98(6):1355–1360. doi: 10.1172/JCI118922. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Burt M. J., George P. M., Upton J. D., Collett J. A., Frampton C. M., Chapman T. M., Walmsley T. A., Chapman B. A. The significance of haemochromatosis gene mutations in the general population: implications for screening. Gut. 1998 Dec;43(6):830–836. doi: 10.1136/gut.43.6.830. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Caforio A. L., Grazzini M., Mann J. M., Keeling P. J., Bottazzo G. F., McKenna W. J., Schiaffino S. Identification of alpha- and beta-cardiac myosin heavy chain isoforms as major autoantigens in dilated cardiomyopathy. Circulation. 1992 May;85(5):1734–1742. doi: 10.1161/01.cir.85.5.1734. [DOI] [PubMed] [Google Scholar]
  9. Codd M. B., Sugrue D. D., Gersh B. J., Melton L. J., 3rd Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. A population-based study in Olmsted County, Minnesota, 1975-1984. Circulation. 1989 Sep;80(3):564–572. doi: 10.1161/01.cir.80.3.564. [DOI] [PubMed] [Google Scholar]
  10. Durand J. B., Bachinski L. L., Bieling L. C., Czernuszewicz G. Z., Abchee A. B., Yu Q. T., Tapscott T., Hill R., Ifegwu J., Marian A. J. Localization of a gene responsible for familial dilated cardiomyopathy to chromosome 1q32. Circulation. 1995 Dec 15;92(12):3387–3389. doi: 10.1161/01.cir.92.12.3387. [DOI] [PubMed] [Google Scholar]
  11. Fatkin D., MacRae C., Sasaki T., Wolff M. R., Porcu M., Frenneaux M., Atherton J., Vidaillet H. J., Jr, Spudich S., De Girolami U. Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N Engl J Med. 1999 Dec 2;341(23):1715–1724. doi: 10.1056/NEJM199912023412302. [DOI] [PubMed] [Google Scholar]
  12. Feder J. N., Gnirke A., Thomas W., Tsuchihashi Z., Ruddy D. A., Basava A., Dormishian F., Domingo R., Jr, Ellis M. C., Fullan A. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet. 1996 Aug;13(4):399–408. doi: 10.1038/ng0896-399. [DOI] [PubMed] [Google Scholar]
  13. Jeunemaitre X., Charru A., Chatellier G., Dumont C., Sassano P., Soubrier F., Ménard J., Corvol P. M235T variant of the human angiotensinogen gene in unselected hypertensive patients. J Hypertens Suppl. 1993 Dec;11(5):S80–S81. [PubMed] [Google Scholar]
  14. Kass S., MacRae C., Graber H. L., Sparks E. A., McNamara D., Boudoulas H., Basson C. T., Baker P. B., 3rd, Cody R. J., Fishman M. C. A gene defect that causes conduction system disease and dilated cardiomyopathy maps to chromosome 1p1-1q1. Nat Genet. 1994 Aug;7(4):546–551. doi: 10.1038/ng0894-546. [DOI] [PubMed] [Google Scholar]
  15. Kaye M. P. The Registry of the International Society for Heart and Lung Transplantation: tenth official report--1993. J Heart Lung Transplant. 1993 Jul-Aug;12(4):541–548. [PubMed] [Google Scholar]
  16. Keeling P. J., Gang Y., Smith G., Seo H., Bent S. E., Murday V., Caforio A. L., McKenna W. J. Familial dilated cardiomyopathy in the United Kingdom. Br Heart J. 1995 May;73(5):417–421. doi: 10.1136/hrt.73.5.417. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Krajinovic M., Pinamonti B., Sinagra G., Vatta M., Severini G. M., Milasin J., Falaschi A., Camerini F., Giacca M., Mestroni L. Linkage of familial dilated cardiomyopathy to chromosome 9. Heart Muscle Disease Study Group. Am J Hum Genet. 1995 Oct;57(4):846–852. [PMC free article] [PubMed] [Google Scholar]
  18. Lechin M., Quiñones M. A., Omran A., Hill R., Yu Q. T., Rakowski H., Wigle D., Liew C. C., Sole M., Roberts R. Angiotensin-I converting enzyme genotypes and left ventricular hypertrophy in patients with hypertrophic cardiomyopathy. Circulation. 1995 Oct 1;92(7):1808–1812. doi: 10.1161/01.cir.92.7.1808. [DOI] [PubMed] [Google Scholar]
  19. Li D., Tapscoft T., Gonzalez O., Burch P. E., Quiñones M. A., Zoghbi W. A., Hill R., Bachinski L. L., Mann D. L., Roberts R. Desmin mutation responsible for idiopathic dilated cardiomyopathy. Circulation. 1999 Aug 3;100(5):461–464. doi: 10.1161/01.cir.100.5.461. [DOI] [PubMed] [Google Scholar]
  20. Limas C. J., Limas C., Goldenberg I. F., Blair R. Possible involvement of the HLA-DQB1 gene in susceptibility and resistance to human dilated cardiomyopathy. Am Heart J. 1995 Jun;129(6):1141–1144. doi: 10.1016/0002-8703(95)90395-x. [DOI] [PubMed] [Google Scholar]
  21. Limas C. J., Limas C. HLA antigens in idiopathic dilated cardiomyopathy. Br Heart J. 1989 Nov;62(5):379–383. doi: 10.1136/hrt.62.5.379. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Merryweather-Clarke A. T., Pointon J. J., Shearman J. D., Robson K. J. Global prevalence of putative haemochromatosis mutations. J Med Genet. 1997 Apr;34(4):275–278. doi: 10.1136/jmg.34.4.275. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Mestroni L., Maisch B., McKenna W. J., Schwartz K., Charron P., Rocco C., Tesson F., Richter A., Wilke A., Komajda M. Guidelines for the study of familial dilated cardiomyopathies. Collaborative Research Group of the European Human and Capital Mobility Project on Familial Dilated Cardiomyopathy. Eur Heart J. 1999 Jan;20(2):93–102. doi: 10.1053/euhj.1998.1145. [DOI] [PubMed] [Google Scholar]
  24. Olson T. M., Michels V. V., Thibodeau S. N., Tai Y. S., Keating M. T. Actin mutations in dilated cardiomyopathy, a heritable form of heart failure. Science. 1998 May 1;280(5364):750–752. doi: 10.1126/science.280.5364.750. [DOI] [PubMed] [Google Scholar]
  25. Raynolds M. V., Bristow M. R., Bush E. W., Abraham W. T., Lowes B. D., Zisman L. S., Taft C. S., Perryman M. B. Angiotensin-converting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy. Lancet. 1993 Oct 30;342(8879):1073–1075. doi: 10.1016/0140-6736(93)92061-w. [DOI] [PubMed] [Google Scholar]
  26. Richardson P., McKenna W., Bristow M., Maisch B., Mautner B., O'Connell J., Olsen E., Thiene G., Goodwin J., Gyarfas I. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation. 1996 Mar 1;93(5):841–842. doi: 10.1161/01.cir.93.5.841. [DOI] [PubMed] [Google Scholar]
  27. Roberts A. G., Whatley S. D., Morgan R. R., Worwood M., Elder G. H. Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda. Lancet. 1997 Feb 1;349(9048):321–323. doi: 10.1016/S0140-6736(96)09436-6. [DOI] [PubMed] [Google Scholar]
  28. Sampietro M., Piperno A., Lupica L., Arosio C., Vergani A., Corbetta N., Malosio I., Mattioli M., Fracanzani A. L., Cappellini M. D. High prevalence of the His63Asp HFE mutation in Italian patients with porphyria cutanea tarda. Hepatology. 1998 Jan;27(1):181–184. doi: 10.1002/hep.510270128. [DOI] [PubMed] [Google Scholar]
  29. Santos M., Clevers H. C., Marx J. J. Mutations of the hereditary hemochromatosis candidate gene HLA-H in porphyria cutanea tarda. N Engl J Med. 1997 May 1;336(18):1327–1328. doi: 10.1056/NEJM199705013361817. [DOI] [PubMed] [Google Scholar]
  30. Sullivan J. L. Iron and the genetics of cardiovascular disease. Circulation. 1999 Sep 21;100(12):1260–1263. doi: 10.1161/01.cir.100.12.1260. [DOI] [PubMed] [Google Scholar]
  31. Tsukamoto H., Horne W., Kamimura S., Niemelä O., Parkkila S., Ylä-Herttuala S., Brittenham G. M. Experimental liver cirrhosis induced by alcohol and iron. J Clin Invest. 1995 Jul;96(1):620–630. doi: 10.1172/JCI118077. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Tuomainen T. P., Kontula K., Nyyssönen K., Lakka T. A., Heliö T., Salonen J. T. Increased risk of acute myocardial infarction in carriers of the hemochromatosis gene Cys282Tyr mutation : a prospective cohort study in men in eastern Finland. Circulation. 1999 Sep 21;100(12):1274–1279. doi: 10.1161/01.cir.100.12.1274. [DOI] [PubMed] [Google Scholar]
  33. Wenzel K., Blackburn A., Ernst M., Affeldt M., Hanke R., Baumann G., Felix S. B., Kleber F. X., Rohde K., Gläser C. Relationship of polymorphisms in the renin-angiotensin system and in E-selectin of patients with early severe coronary heart disease. J Mol Med (Berl) 1997 Jan;75(1):57–61. doi: 10.1007/s001090050087. [DOI] [PubMed] [Google Scholar]
  34. Worwood M. Inborn errors of metabolism: iron. Br Med Bull. 1999;55(3):556–567. doi: 10.1258/0007142991902628. [DOI] [PubMed] [Google Scholar]
  35. de Sousa M., Reimão R., Lacerda R., Hugo P., Kaufmann S. H., Porto G. Iron overload in beta 2-microglobulin-deficient mice. Immunol Lett. 1994 Feb;39(2):105–111. doi: 10.1016/0165-2478(94)90094-9. [DOI] [PubMed] [Google Scholar]

Articles from Heart are provided here courtesy of BMJ Publishing Group

RESOURCES